Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA; Department of Molecular Cellular and Developmental Biology, Yale University School of Medicine, New Haven, CT, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Cell Host Microbe. 2020 Jun 10;27(6):870-878. doi: 10.1016/j.chom.2020.05.008. Epub 2020 May 27.
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Without approved antiviral therapeutics or vaccines to this ongoing global threat, type I and type III interferons (IFNs) are currently being evaluated for their efficacy. Both the role of IFNs and the use of recombinant IFNs in two related, highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, have been controversial in terms of their protective effects in the host. In this review, we describe the recent progress in our understanding of both type I and type III IFN-mediated innate antiviral responses against human coronaviruses and discuss the potential use of IFNs as a treatment strategy for COVID-19.
2019 年冠状病毒病（COVID-19）是由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的全球大流行疾病。由于目前尚未批准用于治疗这一持续全球威胁的抗病毒疗法或疫苗，因此正在评估 I 型和 III 型干扰素（IFN）的疗效。在宿主的保护作用方面，干扰素的作用以及在两种相关的高致病性冠状病毒 SARS-CoV 和 MERS-CoV 中使用重组 IFN，一直存在争议。在这篇综述中，我们描述了目前对 I 型和 III 型 IFN 介导的针对人类冠状病毒的先天抗病毒反应的理解的最新进展，并讨论了将 IFN 用作 COVID-19 治疗策略的潜力。
